WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Big Data Breathes Life into Next-Gen Pharma R&D
I'm For Real
Enter your details once to access all our information and resources
Transdermal Therapeutics is a compound pharmacy committed to providing prescribers the highest quality customized pain management medications for their patients.
whitePaper | March 27, 2023
European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.
whitePaper | July 4, 2023
The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.
whitePaper | June 9, 2022
Anaxomics has developed a novel method of analysis for microarray data based on the generation and subsequent comparison of 2D fingerprints for each sample. Microarray results are incorporated into a protein interaction network and embedded with all sorts of biological and medical data.
whitePaper | February 24, 2023
The WBR Insights research team surveyed 100 leaders from pharmaceutical companies to generate the results featured in this report. The respondents occupy roles in marketing, sales, commercial strategy, and product development.
whitePaper | April 7, 2022
The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy
whitePaper | July 13, 2023
Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE